Formulation

Challenges in Topical Product Development

Challenges in Topical Product Development

Formulating effective topical products is a complex process that requires balancing efficacy, stability, and patient compliance. Here are some common challenges and practical solutions: Poor Drug Penetration Instability of Active Ingredients Phase Separation in Emulsions Grittiness or Texture Issues Preservative System Failure Inconsistent Spreadability & Feel Successful topical formulations require a deep understanding of formulation…

Quality by Design (QbD) in Topical Formulations
|

Quality by Design (QbD) in Topical Formulations

In topical pharmaceutical development, achieving batch-to-batch consistency, therapeutic efficacy, and regulatory compliance requires a Quality by Design (QbD) framework. A well-defined design space based on Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs) ensures an optimized, scalable, and reproducible formulation. Identifying CMAs in Topical Formulations API Attributes: Excipient Functionality: Defining…

Key Considerations for API Source Change in Formulation

Key Considerations for API Source Change in Formulation

Changing the API source requires evaluating its impact on safety, efficacy, stability, and manufacturability. Below are the key factors to assess: Physicochemical Properties Dissolution & Bioavailability Stability Considerations Regulatory & Compliance Manufacturing & Process Impact In-vivo Considerations Risk Assessment & Final Decision Conclusion API source changes demand scientific, regulatory, and process evaluations to prevent any…

SUPAC Guidance on Qualitative Changes in Excipients

SUPAC Guidance on Qualitative Changes in Excipients

SUPAC Guidance on Qualitative Changes The USFDA SUPAC (Scale-Up and Post-Approval Changes) guidance categorizes formulation changes based on their impact on product performance. A qualitative change refers to the replacement or removal of an excipient, classified as a Level 3 change, which is considered major and requires regulatory approval. Key Regulatory Requirements for Level 3…

Is a Bioequivalence (BE) Study Needed When Replacing Crospovidone with Croscarmellose?
|

Is a Bioequivalence (BE) Study Needed When Replacing Crospovidone with Croscarmellose?

A BE study may or may not be required, depending on several factors. Here’s a structured approach to determine whether regulatory agencies like the FDA or EMA would require a BE study for this type of qualitative formulation change: Regulatory Perspective on Excipients in Bioequivalence Regulatory agencies consider excipients when evaluating bioequivalence, especially when they…

Overcoming Solubility Challenges in Pharmaceutical Formulation

Overcoming Solubility Challenges in Pharmaceutical Formulation

Today, let’s dive into the intricate world of overcoming solubility challenges in drug formulation. Join me as we explore the hurdles posed by poor solubility and the ingenious strategies formulated by scientists to tackle this pervasive issue. Solubility Challenges Formulation Strategies Nanosuspensions: Solid Dispersions: Cyclodextrin Complexation: Overcoming solubility challenges is pivotal in developing effective therapies….

End of content

End of content